StreetAlpha.app
Home › Stocks › QNTM

Quantum Biopharma Ltd. (QNTM)

$1.61
▲ +11.81%
LAST CLOSE · NOV 17

Quantum BioPharma develops drug candidates for neurodegenerative, inflammatory, metabolic and alcohol misuse disorders. It last closed at $1.61 on Nov 17, up 11.81% on the day.

AI Auto Pilots
Is QNTM in one of our four AI portfolios? Sign in free to see

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated QNTM in the past 90 days, not enough for a consensus
Average 12-month target
$8.00
▲ 396.9% upside

Based on 1 analyst who set a price target on QNTM in the past 90 days. The average target is $8.00, with a high of $8.00 and a low of $8.00, compared with the last close of $1.61.

Low $8.00Avg $8.00High $8.00
Blue marker: last close $1.61
Highest target$8.00
Average target$8.00
Lowest target$8.00
Latest rating changes
Rodman & RenshawInitiated
Aug 31Buy$8
DateFirmActionRatingPrice target
Aug 31Rodman & RenshawInitiatedBuy$8
Loading…

Technical Analysis

QNTM · as of the Nov 17 close · updated after every close
Downtrend, oversold

The stock is 31% below its 20 day and 76% below its 50 day average. It is 127% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 28), oversold. The nearest support is the Pivot at $1.59, and the nearest resistance the Pivot R1 at $1.70.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityNormal, 12.7%/day
Key levels
$12.4252 week high+671.4%
$3.65200 day average+126.7%
$3.04100 day average+88.8%
$2.8350 day average+75.8%
$2.31Swing high (Nov 9)+43.5%
$2.1120 day average+31.1%
$1.70Pivot R1+5.6%
$1.61Last close
$1.59Pivot−1.2%
$1.51Pivot S1−6.2%
$1.3352 week low−17.4%
Indicators
RSI (14)28.22Oversold below 30Oversold
MACD-0.32Below its signal lineBearish
Stochastic11.5Near the bottom of its rangeOversold
ADX (14)39.7Trending down
Williams %R-76.1Oversold below −80, overbought above −20Neutral
CCI (20)-162.7Oversold below −100, overbought above 100Oversold
Rate of change−27.1%Change over 10 sessionsBearish
ATR (14)$0.20Typical daily range, 12.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for QNTM

What happened before

See how QNTM did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow QNTM usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How QNTM has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in QNTM in the last 90 days.

Loading…

See today’s whale options flow across the market →

QNTM Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲13 buying vs 6 selling
  • ▲Shares held by funds +28.8%
  • ▲Funds holding +1
  • ●No superinvestor moves
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding2827+3.7%
In funds' top 1000–
Held by funds–––
New / increased5 / 83 / 8+18.2%
Reduced / sold out2 / 44 / 3−14.3%
Put/call ratio–––
SuperinvestorsKen GriffinHolding
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See QNTM institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether QNTM is in one of them and how their past QNTM trades turned out.

QNTM in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered QNTM in an article yet. Here's the latest on the wider market.

About Quantum Biopharma

Quantum BioPharma is a biopharmaceutical company based in Toronto that develops drug candidates for neurodegenerative, inflammatory, and metabolic disorders, as well as alcohol misuse. Its lead candidate, Lucid-MS, is being researched as a possible treatment for multiple sclerosis and is at the preclinical stage. The company has also licensed unbuzzd, a dietary supplement drink intended for people who have consumed excess alcohol, to Unbuzzd and Celly U.S. for retail sale. It is also developing a healthcare product for use in hospitals and emergency departments.

Headquarters
Toronto